Registry update — unassessed
The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity: A Pilot Study
Trial registry update: RECRUITING. No results reported in the supplied registry record.
RCTMinor significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Oct 6, 2026 · Discovered: Oct 6, 2026 · Assessed: — · Research update
What it does not prove
- Without reported results, findings or lack thereof on tirzepatide's effect on vasomotor symptoms cannot be established from this source.
- No conclusions about biological aging outcomes can be drawn, as no results are presented.
- A pilot design means findings would require confirmation in larger trials before generalizing to broader populations.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- post-menopausal women with obesity
- Primary outcome
- effect of tirzepatide on vasomotor symptoms and measures of biological aging
- Effect size
- —
- Significance
- Not reported
- Journal
- Mayo Clinic
- Published
- Oct 6, 2026
Sources
Primary source
- Mayo Clinic ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
The purpose of this study is to determine the effect of tirzepatide on vasomotor symptoms and on measures of biological aging.
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.